Full-Time
Venture capital building bioplatform companies
$188k - $258.5k/yr
Cambridge, MA, USA
In Person
See people who can refer or advise you
Flagship Pioneering funds and incubates life-sciences ventures by creating bioplatform companies, forming early-stage NewCos and guiding them to GrowthCos. It identifies broad scientific platforms that can generate multiple products, builds companies around these platforms, and moves them from inception to growth to assemble a multi-product portfolio. Unlike traditional investors, it creates new ventures from scratch and shepherds them through staged development, building a pipeline of category-leading biotech and life-science companies. Its goal is to develop a diverse portfolio of platform-based companies that advance human health and sustainability by delivering multiple products.
Company Size
501-1,000
Company Stage
N/A
Total Funding
$11B
Headquarters
Cambridge, Maryland
Founded
2000
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Flexible Work Hours
Flagship Pioneering has appointed Fidah Alsagoff as Executive Partner and Head of Global Initiatives and Maggie Sahlman as Executive Partner and Head of Fundraising and Investor Relations. The newly created roles aim to strengthen the firm's global innovation ecosystem and accelerate company growth. Alsagoff brings over 30 years of healthcare and life sciences experience. He previously served as Global Head of Life Sciences at Temasek International and held leadership positions in Singapore's healthcare sector. He will lead Flagship's global strategy, building on partnerships with organisations including A*STAR, the National University of Singapore, and the Francis Crick Institute. Sahlman has more than 20 years of institutional capital-raising experience. She previously served as Managing Director at Charlesbank Capital Partners and held senior roles at Houlihan Lokey and Advent International.
Flagship Pioneering has launched Serif Biomedicines, a biotechnology company developing Modified DNA as a new class of medicines, with an initial commitment of $50 million. The Cambridge, Massachusetts-based startup emerges following five years of platform development. Serif Biomedicines is pioneering a novel approach to therapeutics using modified DNA technology. The company was developed within Flagship Pioneering's scientific innovation engine before its formal launch.
Flagship Pioneering has launched Serif Biomedicines with an initial $50 million commitment to develop Modified DNA as a new therapeutic platform. The company emerged after five years of platform development. Serif's Modified DNA technology aims to combine advantages of mRNA and gene therapy whilst addressing limitations like immunogenicity and inefficient nuclear access. The platform enables programmable, scalable, durable and redosable medicines without altering the genome. The company will present preclinical data at an upcoming scientific meeting showing tolerability in non-human primates and sustained gene expression with therapeutic effects following intravenous administration. Serif's initial programmes target rare diseases and immune programming. Founded in 2021 within Flagship Labs, Serif is led by CEO Jacob Rubens and co-founded by Noubar Afeyan, Geoffrey von Maltzahn, Eric Keen and Louisa Helms. The platform is protected by over 20 patent families.
Harbinger Health has announced RESOLVE™, a new category of blood-based multi-cancer detection tests designed to accelerate diagnosis in patients with suspected cancer. The first products are expected to launch commercially in the second half of 2026. The Cambridge-based biotech company raised $100 million in 2025, led by founder Flagship Pioneering, to support product development and its ongoing PROCARES prospective validation study. RESOLVE™ targets the diagnostic gap between symptom presentation and cancer diagnosis, which currently averages five months, during which mortality can increase by up to 8% monthly. The PROCARES study is nearing completion with over 88% of participants enrolled. It follows Harbinger's completed CORE-HH study, which demonstrated effective multi-cancer detection and high specificity in asymptomatic individuals.
Flagship Pioneering and AWS announce collaboration to accelerate drug discovery and life sciences innovation. Apr 01, 2026, 06:30 ET Flagship's early-stage companies to receive AWS cloud credits, technical support, and AI capabilities to accelerate drug discovery and scientific platforms CAMBRIDGE, Mass., April 1, 2026 /PRNewswire/ - Flagship Pioneering, a scientific innovation engine for transformative platforms and products, and Amazon Web Services (AWS) today announced a strategic collaboration to accelerate the development and scaling of breakthrough life sciences companies. Within this collaboration, AWS will be the preferred cloud provider for Flagship, supporting its companies as they build and scale digitally native and AI-native platforms and products across human health, sustainability, and other critical scientific domains. Flagship's early-stage companies will receive comprehensive technical support to fully leverage AWS's cloud and AI services, AWS cloud credits, and go-to-market resources to reach AWS's network of customers. Flagship's internal teams of scientists and engineers, including members of its Pioneering Intelligence Initiative, will also receive specialized support to enhance their company creation and scaling capabilities. "AI is no longer a theoretical tool in the life sciences - it's a catalyst that's fundamentally accelerating how we understand nature and generate breakthroughs," said Avak Kahvejian, President of Flagship Labs and General Partner, Flagship Pioneering. "This collaboration with AWS will enable Flagship Labs and our companies to access more technological capabilities to push scientific boundaries further and faster." "Life science innovation increasingly depends on the ability to compute at scale, experiment rapidly, and move seamlessly from discovery to deployment," said Jason Bennett, Vice President and Global Head of Startups at AWS. "Through this collaboration with Flagship Pioneering, we're providing reliable, secure, and scalable infrastructure and AI capabilities that enable startups rapid experimentation and scaling of breakthrough discoveries, ultimately helping to transform how we approach everything from drug discovery to climate change." The collaboration follows successful collaborations between AWS and Flagship-founded companies, including Moderna and Lila Sciences. About Flagship Pioneering Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health. SOURCE Flagship Pioneering